GlassScriptPhysician profile
Ritika Mahajan
NPI 1285947283
$6,810.05
in general payments reported to CMS, 2019-2025
42 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $273 · 2021: $269 · 2022: $1,172 · 2023: $1,441 · 2024: $1,274 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237 · Education: $75.99 · Travel and Lodging: $8.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.08 |
| Education | $75.99 |
| Travel and Lodging | $8.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $949.87 | 2021-2025 | |
| Ucb, INC. | $639.75 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $606.03 | 2019-2025 | |
| Lilly USA, LLC | $443.70 | 2019-2024 | Kisunla, Emgality, Amyvid |
| Neurocrine Biosciences, INC. | $370.03 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $360.73 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Teva Pharmaceuticals USA, INC. | $313.49 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $303.42 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $254.89 | 2024-2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $227.78 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $179.70 | 2019-2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $179.04 | 2022 | |
| Allergan, INC. | $172.04 | 2019-2021 | |
| Lundbeck LLC | $166.41 | 2020-2025 | Rexulti, Vyepti |
| Acadia Pharmaceuticals INC | $130.65 | 2020-2025 | Nuplazid |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $128.09 | 2019-2025 | |
| Argenx US, INC. | $126.26 | 2024-2025 | Vyvgart Hytrulo |
| Janssen Biotech, INC. | $115.21 | 2025 | |
| Neurelis, INC. | $108.86 | 2022-2025 | Valtoco |
| Genzyme Corporation | $106.82 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $99.23 | 2019-2025 | Rytary, Crexont |
| Takeda Pharmaceuticals U.S.A., INC. | $93.44 | 2024-2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $74.94 | 2022-2025 | Xeomin, Inbrija |
| Vanda Pharmaceuticals INC. | $73.03 | 2024-2025 | Ponvory |
| Impel Pharmaceuticals INC. | $61.73 | 2023 | Trudhesa |
| Sk Life Science, INC. | $61.31 | 2021-2022 | |
| Forte Bio-Pharma LLC | $57.42 | 2025 | Tanlor |
| Livanova USA, INC. | $57.06 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $49.35 | 2022-2023 | Ponvory |
| Eisai INC. | $40.89 | 2022-2023 | |
| Greenwich Biosciences, INC. | $33.75 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $28.41 | 2021 | |
| Octapharma USA, INC. | $26.02 | 2025 | Panzyga |
| Axsome Therapeutics, INC. | $23.46 | 2025 | Symbravo |
| Averitas Pharma INC. | $23.18 | 2023 | Qutenza |
| Mdd US Operations, LLC | $22.86 | 2023 | Gocovri |
| Banner Life Sciences, LLC | $21.83 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.62 | 2022 | |
| Avion Pharmaceuticals | $16.50 | 2022 | |
| Ani Pharmaceuticals, INC. | $15.16 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $13.89 | 2023 | Evrysdi |
| Kyowa Kirin, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritika Mahajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.